

Inflammatory Bowel Disease: Role of the Primary Care Provider in Identification and Management

Anita Afzali, MD, MPH, FACG
Assistant Professor, Department of Internal Medicine
Medical Director
OSU Inflammatory Bowel Disease Center
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center

Financial Disclosures

- **Consultant/Speaker:** Abbvie, UCB, Takeda, Pfizer
- **Advisory Board:** Abbvie, UCB
- **Research Grant Support:** UCB
- **Board Member/Founder:** IBD Horizons® (nonprofit IBD accredited organization)

Learning Objectives

- **Review IBD 101: Epidemiology, Pathophysiology**
- **Understand treatment strategies and therapeutic target goals**
- **Discuss role of the primary care provider in IBD**
- **Develop a health maintenance plan and provide preventative care for a patient with IBD**

Definition and Epidemiology of IBD

- **Idiopathic, chronic inflammatory disease**
 - **Crohn's disease (CD):** any part of GI tract
 - **Ulcerative colitis (UC):** involves only colon
- **Characterized by activation or dysregulation of the immune system**
- **Periods of remission & relapse**
- **Symptoms vary widely based on location and severity**
- **IBD is not irritable bowel syndrome (IBS)**

Increasing Incidence of IBD with Time

Ulcerative colitis

Crohn's disease


- Europe: 24.3 per 100,000 PY
- North America: 19.2
- Asia & Middle East: 6.3
- Europe: 12.7 per 100,000 PY
- North America: 20.2
- Asia & Middle East: 5.0
- Data traditionally from large Canadian & European populations, and analysis of predominantly Caucasian population

In United States:

- Incidence of IBD among African Americans approaching Caucasians
- Incidence of UC among Hispanics is increasing relative to Caucasians
- Limited data of incidence/prevalence of IBD among Asians


SC Ng et al. Lancet October 2017
 Molodecky NA et al. Gastroenterology 2012
 Afzali A. World Gastroenterology News April 2015
 Afzali A. Cross Rk. Inflamm Bowel Dis July 2016

Chronic Inflammation: Proteins Called Cytokines Are the Light Switch



Symptomatology of Ulcerative Colitis


- Altered bowel movements
 - Increased stool frequency
 - Decreased stool consistency
- Abdominal pain
 - LLQ cramping, relieved with defecation
 - Tenesmus
- Blood in stool
- Simple Colitis Activity Index (SCAI)



Author: Connormah_

Symptomatology of Crohn's Disease

- Diarrhea – chronic or nocturnal
- Abdominal pain – post prandial, RLQ, distension
- Weight loss
- Fever
- Rectal bleeding
- Harvey Bradshaw Index (HBI)



Clinical Features of IBD

Common Physical Examination Findings

- Abdominal tenderness
- Palpable mass
- Perianal disease
- Extra-intestinal manifestations

Common Laboratory & Radiographic Findings

- Anemia
- Leukocytosis
- Elevated ESR/CRP*
- Small bowel disease
- Fistulas
- Strictures

Podolsky DK. N Engl J Med. 2002

Differential Diagnosis for IBD

- Clinical symptoms not specific for disease
- DDX: 'IBD Mimickers'
 - Infection:
 - Ileocolonic - bloody diarrhea: *Campylobacter*, *Salmonella*, *E-coli*, *Shigella*
 - Terminal ileum - RLQ pain: *Yersinia enterocolitica*, appendicitis
 - Proctitis - rectal pain: *Chlamydia trachomatis*
 - Ischemia, Radiation, Drugs (NSAIDs)


Endoscopic Features for IBD



- | | |
|---|--|
| <ul style="list-style-type: none"> • Ulcerative Colitis • Contiguous & circumferential • Erythema • Loss of vascular pattern • Friability • Granularity • Edema | <ul style="list-style-type: none"> • Crohn's Disease • Discontinuous, patchy • Aphthous or punched out ulcers • Serpiginous, linear ulcers • Noncaseating granulomas (~5-15%) • Rectal sparing (*more common with CD) • Strictures • Fistulas |
|---|--|



Role of Colonoscopy in IBD

Normal findings of terminal ileum and colon









Components of IBD Diagnosis

- History
- Physical Examination
- Labs
 - CBC, CMP, ESR, CRP, iron studies, vitamin B12, vitamin D, zinc, folate
 - Fecal calprotectin
 - Stool
 - C difficile toxin PCR
 - O&P, Giardia
- Endoscopy
 - Colonoscopy, EGD (if CD suspected)
- Cross-sectional imaging
 - CT or MRI enterography
- Additional diagnostic studies
 - Capsule endoscopy
 - Device assisted balloon enteroscopy

- Clinical course of symptoms
- Laboratory studies
- Endoscopy
- Radiography
- Other

Mill J, Lawrence IC, WJG. 2014
 Kornbluth A, et al. Am J Gastroenterology. 2010





- ### Right Patient, Right Treatment, Right Time
-
- **Integration of clinical variables (i.e. age, gender), disease characteristics, genetic and conventional laboratory testing**
- ⇒ to guide treatment decisions - **INDIVIDUALIZE**
- **Decrease risk of adverse events and disease complications**
 - **Potential to optimize efficacy and outcomes**
 - **Similar model used: Diabetes, hypertension**

Individual Predictive Markers for Severe CD

Marker	Predicted Outcome
Ileal location	Complications, surgery
Location proximal to the last third of ileum	Relapses, surgery
Colonic or rectal disease	Perianal disease
Anal lesions	Disabling disease
Stricturing penetrating behavior at diagnosis	Surgery
Age <40 years	Disabling disease
Smoking	Relapses, complications
Deep colonic ulcers	Surgery
CARD15 variants	Complications, surgery
IBD5/OCTN variants	Perianal disease
Antiglycan antibodies	Complications, surgery
Antibacterial antibodies	Complications, surgery

Falvey JD et al. Inflamm Bowel Dis 2015

Individual Predictive Markers for Severe UC

Marker	Predicted Outcome
Extensive colitis	Colectomy, cancer, mortality
Colitis extension	Colectomy
Sclerosing cholangitis	Cancer
Extra-intestinal manifestations	Colectomy
Young age	Colectomy, cancer
Non smoking	Relapses, colectomy
Systemic inflammation	Colectomy
No response to first line therapy	Colectomy
No mucosal healing 1 year after diagnosis	Colectomy
HLA variants	Colectomy
ANCA	No response to anti-TNF

Falvey JD et al. Inflamm Bowel Dis 2015

IBD Medicine Cabinet

Over-the-Counter

Antibiotics


5-Aminosalicylates/mesalamine

Corticosteroids, budesonide

Immunomodulators – AZA/6MP, MTX

Biologics – Target-protein specific

New Targets: Mechanisms of Action Biologics IBD




IBD Treatment Strategy

“Top-down” Strategy

- Early, appropriate use of biologic as initial treatment
- Induces rapid clinical response
- May enhance quality of life

“Step-up” Strategy

- Standard, sequential treatment for remission and maintenance
- Cost-effective
- Minimal side effects



Treatment Approach Strategies

Low risk of disease progression

“Top-down”: may over-treat and expose patients to costs, risks of immunosuppression


High risk of disease progression

“Step-up”: may postpone adequate therapy in aggressive disease and results in disease progression, complications, morbidity

Protein Target Specific: Biologics in IBD

- Revolutionized treatment and management of UC and CD
- Why do we use them?
 - Very effective
 - Reduces hospitalization, surgery
 - Steroid free remission
 - Improved quality of life
 - Changes the natural history of disease**
- Limitations: costs, misinformation

TEMPORAL TRENDS OF COLECTOMY UC



Kaplan GG et al. AJG 2012

Since introduction of biologic agents/anti-TNFs, decrease in total colectomy in UC patients

Risks of Anti-TNFs and Immunomodulators

If 10,000 patients were treated for 1 year

Event	Estimated Frequency
NHL (baseline)	2/10,000
NHL (on IMs)	4-9/10,000
NHL (on anti-TNF with prior IMs)	4-9/10,000
Hepatosplenic T-cell lymphoma	Unknown
Death from sepsis (lower for younger patients)	4/1,000
Tuberculosis	5/10,000


Anti-TNF, anti-tumor necrosis factor; IMs, immunomodulators; NHL, non-Hodgkin lymphoma.
Table adapted from Siegel CA. In *Inflammatory Bowel Disease: Translating Basic Science Into Clinical Practice*. Wiley, 2010.

Safety/Toxicity of Anti-TNFs

- Serious Infections in Crohn's disease
 - Anti-TNF increases risk 43%
 - Prednisone increases risk 57%
 - Opioid use doubles the risk
 - Active Crohn's Disease - Moderate to severe more than doubles the risk


Risks of Corticosteroids

Oral steroids are effective for inducing remission, but not for maintaining remission.
Oral Corticosteroids Are NOT a Long-term Option
Approximately 50% of all patients who use corticosteroids will experience adverse events



Afzali, A et al. Medical Therapy of Ulcerative Colitis. 2014
Lichtenstein GR, et al. Gastroenterol. 2006


THE EVOLUTION OF CROHN'S DISEASE: INFLAMMATION LEADS TO DAMAGE



Over a 20-year period, 88% risk of developing stricturing (18%) or penetrating (70%) disease

Cosnes J et al. Inflamm Bowel Dis. 2002

Natural History Of Ulcerative Colitis




Risk of colectomy: 24% after 10 years
~ 30% after 20 years

Significant Increased risk of cancer

Adapted from Langholz E, et al. Gastroenterol 1994

Update in the Evolution of Treatment Goals & Strategies




Adapted CCFCA Canada Webinar 2015

Clinical versus Endoscopic Indices

- Does not correlate with clinical course of disease
- Does not prevent long-term complications of disease
- Symptoms do not always correlate with severity of mucosal disease (bullet)
- Crohn's Disease Activity Index (CDAI) (sub-bullet)
- Crohn's Disease Endoscopic Index Severity Score (CDEIS) poor correlation (sub-bullet)

Modigliani M, et al. Gastroenterology 1990

Impact of Mucosal Healing (MH): Surgical Outcomes



Frosile KF, et al. Gastroenterology 2007

Crohn's Disease: Therapeutic Targets

Clinical	Endoscopic	Imaging	Biomarkers	Histologic	Patient-Reported Outcomes (PROs)
Resolution of abdominal pain	Absence of ulcerations	Resolution of lesions	Normalization of CRP, FC	No active inflammation	Direct patient report of function and symptoms
Normalization of bowel habits					
TARGET	TARGET	TARGET	NOT TARGET	NOT TARGET	FUTURE*

Selecting Therapeutic Targets in IBD (STRIDE): Peyrin-Biroulet L, et al. Am J Gastroenterol 2015

Ulcerative Colitis: Therapeutic Targets

Clinical	Endoscopic	Imaging	Biomarkers	Histologic	Patient-Reported Outcomes (PROs)
Resolution of rectal bleeding	Mayo clinic endoscopy score of 0 or 1	Resolution of lesions	Normalization of CRP, FC	No active inflammation	Direct patient report of function and symptoms
Normalization of bowel habits					
TARGET	TARGET	NOT TARGET	NOT TARGET	NOT TARGET	FUTURE*

Selecting Therapeutic Targets in IBD (STRIDE): Peyrin-Biroulet L, et al. Am J Gastroenterol 2015

Impact of IBD

Medical Impact

- 85% of patients suffer from diarrhea¹
- 51% of patients were hospitalized in the last 3 years²
- 64% required surgery²
- ~90% of CD will have surgery in their lifetime

Work Disability Impact

- 55% missed work due to disease in the past year³
- 5.3% become permanently work disabled²

Emotional Impact

- 70% of patients report anxiety or depression, compared with 30% of population norms⁴


1. Knutson D, et al. Am Fam Physician. 2003.
 2. Ananthakrishnan AN, et al. Am J Gastroenterol. 2008.
 3. Kiebles JL, et al. Inflamm Bowel Dis. 2010.
 4. Faagan BG, et al. Am J Gastroenterol. 2009.

Health & Economic Burden of IBD

- Every year in the US, IBD accounts for:
 - 1,300,000 physician visits
 - 92,000 hospitalizations
- Direct treatment costs for IBD patients: \$6.3 billion
- Indirect costs: additional \$5.5 billion
- In 2006, total costs of Crohn's disease in the U.S. were estimated \$10.9-\$15.5 billion

Park KT and Bass D. Inflamm Bowel Dis 2011
 Yu AP et al. Curr Med Res Opin 2008

Clinical Consequences of Delayed IBD Diagnosis



Anderson NN, et al. JAMA 2014
 Kotlyar D, et al. Gastroenterol. 2015
 Lichtenstein GR, et al. Am J Gastroenterol. 2012

The Role of Primary Care Clinicians in IBD

Initial recognition of signs + symptoms, Gastroenterology Consultation, Diagnostic work up

Ongoing health maintenance for the IBD patient

What is the Role of Primary Care Clinicians in IBD?

PCP Checklist in IBD Care

<input type="checkbox"/> Vaccinations	<input type="checkbox"/> Pap smears
<input type="checkbox"/> Monitoring laboratory studies (WBC, Cr, LFTs, glucose)	<input type="checkbox"/> Smoking cessation
<input type="checkbox"/> Iron deficiency	<input type="checkbox"/> Dermatological evaluation
<input type="checkbox"/> Osteoporosis (DEXA)	<input type="checkbox"/> Psychosocial factors
<input type="checkbox"/> Cancer (surveillance)	<input type="checkbox"/> Sexual/reproductive health
<input type="checkbox"/> Cardiovascular disease	<input type="checkbox"/> Ophthalmologic evaluation
<input type="checkbox"/> Monitoring IBD-related complications, disease relapse	<input type="checkbox"/> Medication adherence

Sinclair JA, et al. Gastroenterology. 2012
 Bennett A, et al. World J Gastroenterol. 2015
 Gikas A. Int J Gen med. 2014

Lack of Primary Care

- Many patients with IBD: young, no other comorbid illnesses
- Gastroenterologist will often be their only physician
- IBD patients receive less preventive health services than general population patients

Selby L et al. Inflamm Bowel Dis 2008

Preventative Health in IBD

- **Barriers in the implementation of preventative services:**
 - Lack of consensus of which provider should offer services: PCP vs GI?
 - More focus on disease/symptom control
 - Disease develops 2nd/3rd decade of life, when number of preventive services is few – overlooked?
- Need to improve preventative strategies
- Pay-for-Performance strategies and quality metrics increasingly being adopted
 - AGA IBD Quality Metrics – Health Care Maintenance

Selby L et al. Inflamm Bowel Dis 2008

Categories for Preventative Health


- Vaccinations/immunizations
- Cancer screening
- Smoking cessation
- Osteoporosis
- General health: depression, blood pressure, glucose monitoring, eye exam
- Laboratory examination

Vaccinations

- **Goal: Infection prevention in an ‘at risk’ immunosuppressed population**
- In general, IBD patients should not deviate from general population immunization schedule
- **Exceptions:**
 - Early dosing: Prevnar, Pneumovax, Zoster*
 - Live virus vaccinations: contraindicated with immunosuppression

Sands BE et al. Inflamm Bowel Dis 2004

CDC Immunization Schedule, 2015 Aged 0 – 18 years



<http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf>

Immunization Schedule and IBD

- IBD patients can be vaccinated following the *standard guidelines* applicable to general population
- *Routine vaccinations* recommended to be followed for most IBD patients
- *Lives vaccinations* are contraindicated in the immunocompromised patients

Expert Consensus: IBD Immunocompromised Patient

- Treatment with glucocorticoids:
>prednisone 20mg/d or equivalent for 2 weeks or more
- Ongoing treatment with 6-mercaptopurine, azathioprine, methotrexate and antiTNF therapy
- Within 3 months of stopping immunosuppressive therapies
- Significant protein-calorie malnutrition

Sands BE et al. Inflamm Bowel Dis 2004

Rotavirus (LIVE virus)

- Rotarix at ages 2 and 4 months or RotaTeq at ages 2, 4, and 6 months
- If levels of biologic drug are detectable, rotavirus is relatively contraindicated in the newborn
 - Mothers on anti-TNF therapy during pregnancy
 - Give vaccine to newborn infant at 6 months (or none)

Human Papilloma Virus (HPV)

- Most common sexually transmitted infection in the world
- High risk types (e.g. type 16, 18) associated with 70% of all cervical and anogenital cancers
- Higher incidence of abnormal Pap smears in women with IBD
- Immunosuppressive therapy and smoking exhibits association between IBD and cervical dysplasia vs diagnosis of IBD alone

Singh H et al. Gastroenterology 2009

HPV Vaccination Recommendation

- HPV under vaccination: Misconception that HPV not adult vaccine or assumption patient already vaccinated
- Vaccination can be used for all IBD patients including immunocompromised
- Both males and females should get vaccinated
- Annual pap smears recommended for women on immunosuppressant

Chaudrey K et al. WJG 2015

Pneumococcal Vaccine

- *Streptococcus pneumoniae* (pneumococcus) is the leading cause of bacteremia, meningitis, and pneumonia in adults in the U.S.
- Major risk factors applicable to IBD: >65 yrs or older, smoking and use of immunosuppressive agents

Pneumococcal Vaccination Recommendations

- 2 types: PPSV23 (Pneumovax) and PCV13 (Prennar)
 - PPSV23 commonly used, recommended for all adults
- For adults already received 4 doses during childhood, first revaccination to be given 5 yrs after last dose, then *lifetime* revaccination at age 65yrs
- If not vaccinated as child, 2 doses given 8 weeks apart, then revaccination at 5 years, then age 65

Pneumococcal Vaccination Recommendations in IBD

- PPSV23 is the commonly used, recommended for all adults
- Immunocompromised IBD patients:
 - CDC and ACIP recommends PCV13 given in addition to PPSV23
 - PCV13 preferred before PPSV23
 - If no prior vaccine: PCV13 then 8 weeks later PPSV23; then 5 yrs after last dose PPSV23, then *lifetime* revaccination at age 65yrs
 - If prior vaccine: PCV13 dose at least 1 year after PPSV23; then 5yrs; then lifetime at 65yrs
- Interval between vaccine and initiation of immunosuppressive at least 2 weeks

Chaudrey K et al. WJG 2015

Influenza Vaccine in IBD

- Infectious viral illness that can be fatal as primary infection or complicated by superimposed bacterial infection
- Annual vaccination recommended in all patients > 50 years old
- All IBD patients
 - Antigenic drift leads to new annual vaccine
 - Intranasal is LIVE vaccine
- Safe, well tolerated and risk for IBD-flare low
- Combination therapy affects vaccine response and associated with lower titers

Rahier JF et al. Gut 2011
Cullen G et al. Gut 2012

More Vaccinations in IBD

- **Td/Tdap (Tetanus, Diphtheria and acellular Pertussis):**
 - Childhood DTaP 5 series injection, Td every 10 years
 - For adults, replace 1 Td booster with Tdap
 - Tetanus: No difference between inactive IBD and healthy controls
- **Meningococcal:**
 - Included risk factors: household crowding/college, military recruits, chronic underlying illness, travel in epidemic regions
 - MCV4 vaccine, 2 doses at least 2mo apart
 - First year college students up to age 21 years
 - Immunogenic profile in IBD not studied
- **Hepatitis A, B virus:**
 - high risk, all who wish, all IBD patients

Chaudrey K et al. WJG 2015

Live Virus Vaccines

- “Live virus” vaccine – contains ‘living’ virus that is able to produce immunity, usually without causing illness
 - Bacille Calmette-Guerin (BCG)
 - Influenza inhaled (LAIV) – parenteral attenuated
 - Measles, Mumps, Rubella (MMR)
 - Typhoid (oral) – parenteral attenuated
 - Vaccinia (smallpox)
 - Varicella (chickenpox)
 - Yellow Fever
 - Zoster (Herpes, Shingles)*

Live Virus Vaccines and IBD

- Contraindicated in patients on anti-TNF therapy
 - Debate on whether they can be given when patient on azathioprine/6-MP/methotrexate alone
- Theoretical concerns:
 - Reactivation of underlying disease
 - Disseminated disease caused by live virus

Vaccinations in IBD Summary

- Quick Reference Summary

Vaccine	How often	Live vaccine	Patients on immunosuppressive therapy
Influenza (Flu Vaccine)	1 dose every year	Nasal spray	Use flu shot only
Varicella (Chicken Pox)	If no documented immunity: 2 doses 4-8 wk apart	Yes	Contraindicated
Mumps, mumps, rubella	If no documented immunity: 2 doses, 4 wk apart	Yes	Contraindicated
Zoster (Shingles)	1 dose starting at age 60 yr or older	Yes	Contraindicated
Tetanus, Diphtheria, Acellular Pertussis (Td/Tdap)	If no prior vaccination: 3 doses (0, 1, 6-12), Then 1 dose of Tdap followed by a booster of Td every 10 yr	No	Follow recommended regimen
Human papilloma virus	Female: 3 doses through age 26 (0, 2 and 6 mo) Male: 3 doses through age 26 (0, 2 and 6 mo)	No	Follow recommended regimen
Pneumococcal (pneumonia vaccine) for subset of patients	If no prior vaccination: (0, 2 then 5 yr) 1 dose at 65 If had prior vaccination: 1 dose 5 yr after the last dose and 1 dose at age 65	No	Follow recommended regimen
Meningococcal (meningitis vaccine) for subset of patients	2 doses, 2 mo apart	No	Follow recommended regimen
Hepatitis A	2 doses, 6 mo apart	No	Follow recommended regimen
Hepatitis B	3 doses (0, 1 and 6 mo)	No	Follow recommended regimen

Taken from Chaudrey K et al. WJG 2015

Categories for Preventative Health

- Vaccinations/immunizations
- Cancer screening
- Smoking cessation
- Osteoporosis
- General health: depression, blood pressure, glucose monitoring, eye exam
- Laboratory examination

Cancer Screening: Colorectal Cancer in IBD

- Meta-analysis of population-based studies
- Pooled SIR of CRC in IBD: 1.7 (95%CI 1.2-2.2)
- High Risk Groups:
 - Extensive colitis: SIR 6.4 (95%CI 2.4-17.5)
 - IBD diagnosis before age 30: SIR 7.2 (95%CI 2.9-17.8)
 - PSC: RR 9.13 (95% CI 4.52-18.5)
- Recommendations:
 - Surveillance colonoscopy every 1-2 years after 8 years diagnosis
 - Start surveillance immediately in patients with PSC

Lutgens M et al. Inflamm Bowel Dis 2013

Cancer Screening: Skin Cancer in IBD

- Recommendations:
 - Screening: Annual skin examination by Dermatology if on immunosuppressives
 - Sunscreen in all sun-exposed areas

IBD overall		
Medication	Melanoma	NMSC
Any use		
5-ASA	1.06 (0.77-1.45)	0.99 (0.92-1.08)
Biologic	1.88 (1.08-3.29)	1.14 (0.95-1.36)
Thiopurine	1.10 (0.72-1.67)	1.85 (1.66-2.05)

Long MD et al. Gastroenterology 2012

Categories for Preventative Health

- Vaccinations/immunizations
- Cancer screening
- Smoking cessation
- Osteoporosis
- General health: depression, blood pressure, glucose monitoring, eye exam
- Laboratory examination

Smoking and IBD

- The association of smoking in IBD is complex
 - Effect on Crohn's disease - detrimental
 - Effect on Ulcerative colitis - protective
- Smoking chemicals: nicotine, free radicals and carbon monoxide
 - Targets mucus layer, cytokines, macrophage function and microvasculature

Smoking and IBD

- Two-fold risk of CD (males, early adult onset)
- Two-fold risk of disease progression
- Increased risk for change in disease location ileal or colonic to ileocolonic
- Higher risk or need for steroids (females)
- Increased risk for extraintestinal manifestations of disease (arthritis, skin)

Lakatos PL et al. Inflamm Bowel Dis 2013

Smoking and IBD

- How much is too much?
- Light smokers (1-10 cig/d) vs. Heavy (>10 cig/d):
- BOTH associated with active disease, hospitalization rate and intestinal resection
- Passive smokers: increased risk for need of therapy - immunosuppression (p=0.039) and infliximab (p=0.013); risk for pouchitis (p=0.023)

Van der Heide F et al. Inflamm Bowel Dis 2009
Seksik P et al. Inflamm Bowel Dis 2009

Smoking and IBD

- Negative impact on cancer risk and cardiovascular/pulmonary disease still far outweighs any IBD benefits
- Complete smoking cessation always advised (regardless of CD or UC)
- Smoking cessation discussion only documented ~50% current smokers
- Better efforts needed



Davis J et al. Inflamm Bowel Dis 2013

Categories for Preventative Health

- Vaccinations/immunizations
- Cancer screening
- Smoking cessation
- Osteoporosis
- General health: depression, blood pressure, glucose monitoring, eye exam
- Laboratory examination

Bone Health and IBD

- Osteoporosis reported up to 40% in IBD
- ACG/AGA Practice Guidelines for Screening Recommendations in IBD:
 - Steroid use (>3 mo)
 - History of low trauma fracture
 - Hypogonadism
 - Post-menopausal Men/Women >50 yrs
- Recommendations: DEXA, minimize steroid use, adequate calcium/vitamin D



Bernstein CN et al. Gastroenterology 2003
Bernstein CN et al. ACG 2003

Vitamin D and IBD

- ~50% of IBD patients have Vitamin D deficiency
- Lower levels of Vitamin D (<20ng/mL):
 - Higher risk for hospitalization (OR 2.1)
 - Need for surgery (OR 1.8)
- Vitamin D supplementation reduced frequency of disease relapse in CD vs. placebo (p=.06)
- Recommendations: Annual serum 25(OH)-D levels

Mouli VP and Ananthkrishnan AN. Aliment Pharmacol Ther 2014

Categories for Preventative Health

- Vaccinations/immunizations
- Cancer screening
- Smoking cessation
- Osteoporosis
- General health: depression, blood pressure, glucose monitoring, eye exam
- Laboratory examination

Depression and IBD

- Prevalence of depression (other anxiety d/o) may influence response to treatment and quality of life, irrespective of disease or symptom severity
- Rates of depression 15 – 35% in IBD
- Two-fold increase risk compared to controls
 - 27.2% vs. 12.3%, OR 2.20 (95% CI 1.64-2.95)
- Recommendations: Clinical assessment/counseling, therapy, medications

Walker JR et al. Am J Gastroenterol 2008

General Health in IBD

- Blood Pressure Screening
 - Risk for secondary HTN related to medications
- Glucose Monitoring
 - Risk for steroid-induced diabetes
- Ophthalmologic Exam
 - Risk for cataracts/glaucoma with chronic steroid use; optic neuritis, iritis/uveitis, episcleritis EIMs
 - Recommendation: Annual Eye Exam



Categories for Preventative Health

- Vaccinations/immunizations
- Cancer screening
- Smoking cessation
- Osteoporosis
- General health: depression, blood pressure, glucose monitoring, eye exam
- Laboratory examination

Tuberculosis and IBD

- **Exposure history:**
 - PPD or TB Quantiferon, Chest Xray, referral to ID
- **Tuberculin skin testing PPD:**
 - >5mm POSITIVE; BCG vaccine older than 10 yrs doesn't affect results
- **Quantiferon and T-Spot:**
 - ? More expensive; Benefit in BCG treated
- **False negatives in setting of immunosuppression**
- **Recommendations: screen for TB prior to initiation of immunosuppressants; then every 1-2 years**

Anemia and IBD

- **Prevalence of anemia as high as 74%**
- **Iron Deficiency and Anemia of Chronic Disease are most common**
 - Other - B12 deficiency and drug associated (i.e. azathioprine)
- **Recognized as a frequent extraintestinal manifestation**
- **Common cause of fatigue and hair loss**
- **Recommendations: At least annual iron panel/ferritin, Folate, Vitamin B12; supplement PO or IV based on severity**

Reinisch W et al. Journal of Crohn's & Colitis 2013
Gisbert JP, Gomollon F. Am J Gastroenterol 2008

Laboratory Exams and IBD

Drug	Medication-specific Monitoring
Mesalamine/5ASA	Serum creatinine annual or biannual
Corticosteroids	Annual DEXA Annual Eye exam
Thiopurines	TPMT, thiopurine methyltransferase prior to initiation CBC weekly x 1 month, then at least every 3 months LFTs every 3 months Annual skin examination
Methotrexate	Periodic CBC, LFTs every 3 months
Biologics	TB and Hepatitis serologies prior to initiation 1-2yrs TB test Periodic CBC, LFTs every 3-6 months

**Baseline labs prior to initiation of therapy helpful:
CBC, CMP, ESR/CRP
Nutrition labs at least annually**

Adapted from Moscandrew M et al. Inflamm Bowel Dis 2009

OSUWMC IBD CENTER: Precision Medicine

- **Multidisciplinary Case Conference: First Tuesday of each month**
- **IBD-Surgery Clinic: Shared visits starting January 2018**
- **IBD-Pharmacy Clinic**
- **Pediatric-to-Adult IBD Transition Clinic with NCH**
- **Telemedicine in IBD**
- **Clinical trials: 10+ studies to come**
- **IBD Fellowship at OSU (4th year)**
- **Largest IBD Symposium in Columbus and Midwest: Save the Date March 24, 2018**
- **And this is just the beginning!**